The FDA has cleared two magnesium-based bone graft substitutes from Bone Solutions, for pediatric use in patients 6 years and older.
The products, Mg Osteocrete and Mg Osteoinject, are designed to treat bone voids or defects resulting from trauma, tumors or cysts in the extremities or pelvis. Mg Osteoinject is also used in the outpatient Sclerograft procedure for unicameral bone cysts, according to an Oct. 21 news release from the medical device company.
The grafts are formulated with magnesium oxide and phosphate compounds to promote bone regeneration and osteoblast activity. The materials are moldable or injectable after mixing and are radiopaque for use in surgical settings.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
